These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 18676143)

  • 21. Discovery and characterization of the N-phenyl-N'-naphthylurea class of p38 kinase inhibitors.
    Cirillo PF; Hickey ER; Moss N; Breitfelder S; Betageri R; Fadra T; Gaenzler F; Gilmore T; Goldberg DR; Kamhi V; Kirrane T; Kroe RR; Madwed J; Moriak M; Netherton M; Pargellis CA; Patel UR; Qian KC; Sharma R; Sun S; Swinamer A; Torcellini C; Takahashi H; Tsang M; Xiong Z
    Bioorg Med Chem Lett; 2009 May; 19(9):2386-91. PubMed ID: 19356929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells.
    Kim MH; Kim M; Yu H; Kim H; Yoo KH; Sim T; Hah JM
    Bioorg Med Chem; 2011 Mar; 19(6):1915-23. PubMed ID: 21353571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigation of the differences in activity between hydroxycycloalkyl N1 substituted pyrazole derivatives as inhibitors of B-Raf kinase by using docking, molecular dynamics, QM/MM, and fragment-based de novo design: study of binding mode of diastereomer compounds.
    Caballero J; Alzate-Morales JH; Vergara-Jaque A
    J Chem Inf Model; 2011 Nov; 51(11):2920-31. PubMed ID: 22011048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fused thiophene derivatives as MEK inhibitors.
    Laing VE; Brookings DC; Carbery RJ; Simorte JG; Hutchings MC; Langham BJ; Lowe MA; Allen RA; Fetterman JR; Turner J; Meier C; Kennedy J; Merriman M
    Bioorg Med Chem Lett; 2012 Jan; 22(1):472-5. PubMed ID: 22119475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pyrazolopyridine inhibitors of B-RafV600E. Part 2: structure-activity relationships.
    Wenglowsky S; Ahrendt KA; Buckmelter AJ; Feng B; Gloor SL; Gradl S; Grina J; Hansen JD; Laird ER; Lunghofer P; Mathieu S; Moreno D; Newhouse B; Ren L; Risom T; Rudolph J; Seo J; Sturgis HL; Voegtli WC; Wen Z
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5533-7. PubMed ID: 21802293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hit to lead optimization of pyrazolo[1,5-a]pyrimidines as B-Raf kinase inhibitors.
    Gopalsamy A; Ciszewski G; Shi M; Berger D; Hu Y; Lee F; Feldberg L; Frommer E; Kim S; Collins K; Wojciechowicz D; Mallon R
    Bioorg Med Chem Lett; 2009 Dec; 19(24):6890-2. PubMed ID: 19884006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.
    King AJ; Patrick DR; Batorsky RS; Ho ML; Do HT; Zhang SY; Kumar R; Rusnak DW; Takle AK; Wilson DM; Hugger E; Wang L; Karreth F; Lougheed JC; Lee J; Chau D; Stout TJ; May EW; Rominger CM; Schaber MD; Luo L; Lakdawala AS; Adams JL; Contractor RG; Smalley KS; Herlyn M; Morrissey MM; Tuveson DA; Huang PS
    Cancer Res; 2006 Dec; 66(23):11100-5. PubMed ID: 17145850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, modification and 3D QSAR studies of novel 2,3-dihydrobenzo[b][1,4]dioxin-containing 4,5-dihydro-1H-pyrazole derivatives as inhibitors of B-Raf kinase.
    Yang YS; Li QS; Sun S; Zhang YB; Wang XL; Zhang F; Tang JF; Zhu HL
    Bioorg Med Chem; 2012 Oct; 20(20):6048-58. PubMed ID: 22985962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitors.
    Vasbinder MM; Aquila B; Augustin M; Chen H; Cheung T; Cook D; Drew L; Fauber BP; Glossop S; Grondine M; Hennessy E; Johannes J; Lee S; Lyne P; Mörtl M; Omer C; Palakurthi S; Pontz T; Read J; Sha L; Shen M; Steinbacher S; Wang H; Wu A; Ye M
    J Med Chem; 2013 Mar; 56(5):1996-2015. PubMed ID: 23398453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Computational study on the interaction of N1 substituted pyrazole derivatives with B-raf kinase: an unusual water wire hydrogen-bond network and novel interactions at the entrance of the active site.
    Alzate-Morales JH; Vergara-Jaque A; Caballero J
    J Chem Inf Model; 2010 Jun; 50(6):1101-12. PubMed ID: 20524689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors.
    Buckmelter AJ; Ren L; Laird ER; Rast B; Miknis G; Wenglowsky S; Schlachter S; Welch M; Tarlton E; Grina J; Lyssikatos J; Brandhuber BJ; Morales T; Randolph N; Vigers G; Martinson M; Callejo M
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1248-52. PubMed ID: 21211972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stabilization of a closed kinase conformation induces RAF dimerization.
    Cancer Discov; 2013 Jul; 3(7):715. PubMed ID: 23847340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 5-amino-pyrazoles as potent and selective p38α inhibitors.
    Das J; Moquin RV; Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Newitt JA; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2010 Dec; 20(23):6886-9. PubMed ID: 21035336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel ATP competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the series.
    Oubrie A; Kaptein A; de Zwart E; Hoogenboom N; Goorden R; van de Kar B; van Hoek M; de Kimpe V; van der Heijden R; Borsboom J; Kazemier B; de Roos J; Scheffers M; Lommerse J; Schultz-Fademrecht C; Barf T
    Bioorg Med Chem Lett; 2012 Jan; 22(1):613-8. PubMed ID: 22119462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): increasing cellular potency through optimization of a distal heteroaromatic group.
    Suijkerbuijk BM; Niculescu-Duvaz I; Gaulon C; Dijkstra HP; Niculescu-Duvaz D; Ménard D; Zambon A; Nourry A; Davies L; Manne HA; Friedlos F; Ogilvie LM; Hedley D; Lopes F; Preece NP; Moreno-Farre J; Raynaud FI; Kirk R; Whittaker S; Marais R; Springer CJ
    J Med Chem; 2010 Apr; 53(7):2741-56. PubMed ID: 20199087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 4-Amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors.
    Xu G; Abad MC; Connolly PJ; Neeper MP; Struble GT; Springer BA; Emanuel SL; Pandey N; Gruninger RH; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4615-9. PubMed ID: 18653333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding.
    Emmitte KA; Adjabeng GM; Andrews CW; Alberti JG; Bambal R; Chamberlain SD; Davis-Ward RG; Dickson HD; Hassler DF; Hornberger KR; Jackson JR; Kuntz KW; Lansing TJ; Mook RA; Nailor KE; Pobanz MA; Smith SC; Sung CM; Cheung M
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1694-7. PubMed ID: 19237286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors.
    Gould AE; Adams R; Adhikari S; Aertgeerts K; Afroze R; Blackburn C; Calderwood EF; Chau R; Chouitar J; Duffey MO; England DB; Farrer C; Forsyth N; Garcia K; Gaulin J; Greenspan PD; Guo R; Harrison SJ; Huang SC; Iartchouk N; Janowick D; Kim MS; Kulkarni B; Langston SP; Liu JX; Ma LT; Menon S; Mizutani H; Paske E; Renou CC; Rezaei M; Rowland RS; Sintchak MD; Smith MD; Stroud SG; Tregay M; Tian Y; Veiby OP; Vos TJ; Vyskocil S; Williams J; Xu T; Yang JJ; Yano J; Zeng H; Zhang DM; Zhang Q; Galvin KM
    J Med Chem; 2011 Mar; 54(6):1836-46. PubMed ID: 21341678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and biological evaluation of novel (E)-α-benzylsulfonyl chalcone derivatives as potential BRAF inhibitors.
    Li QS; Li CY; Lu X; Zhang H; Zhu HL
    Eur J Med Chem; 2012 Apr; 50():288-95. PubMed ID: 22361686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 3: an increase in aqueous solubility via the disruption of crystal packing.
    Wenglowsky S; Moreno D; Rudolph J; Ran Y; Ahrendt KA; Arrigo A; Colson B; Gloor SL; Hastings G
    Bioorg Med Chem Lett; 2012 Jan; 22(2):912-5. PubMed ID: 22209462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.